Collins Helen Louise's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Jun 22, 2026
- Accession no.
- 0001701247-26-000010
- Filed
- Jun 22, 2026
- Trade date
- Jun 17, 2026
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $219.0K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Collins Helen LouiseCIK 0001701247 | Officer (CHIEF MEDICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Common Stock | MOption exerciseAcquired | +5,000 | $2.48 | +$12,400 | 30,000 | Direct | |
| Jun 17, 2026 | Common Stock | SSaleDisposed | −1,268 | $42.83F3 | −$54,308.44 | 28,732 | Direct | |
| Jun 17, 2026 | Common Stock | SSaleDisposed | −2,599 | $43.87F4 | −$114,018.13 | 26,133 | Direct | |
| Jun 17, 2026 | Common Stock | SSaleDisposed | −1,133 | $44.74F5 | −$50,690.42 | 25,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Common Stock | MOption exerciseDisposed | −5,000 | $0.00 | $0 | 121,268 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $42.295 to $43.2752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $43.30 to $44.2925. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $44.3005 to $44.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.